Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours
NCT03620643
Study timeline
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
What this registered study describes
Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours is a interventional study listed under registry identifier NCT03620643. Its last published status is COMPLETED. Registry status does not establish that enrollment is currently open at every study site.
The published record lists 4 condition label(s), 2 intervention label(s), and 3 sponsor/collaborator entry or entries. The structured information below allows these links to be examined individually; intervention registration is not an efficacy claim.
Source: the original ClinicalTrials.gov study record. Always check the protocol, eligibility, dates, results (when posted), and contacts at the original source.
Conditions
Interventions
Sponsors & collaborators
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03620643 on ClinicalTrials.gov ↗How to interpret this record
CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.